fbpx

Category

Lundbeckfonden Ventures
Sibofimloc (EB8018/TAK-018) is a first-in-class, orally administered, gut-restricted small molecule designed to reduce inflammation underlying Crohn’s disease Sibofimloc binds FimH, a novel microbiome-derived therapeutic target validated by Enterome, to selectively disarm virulent bacteria in the gut that can cause inflammation without disrupting the local microbiome Sibofimloc is advancing through clinical development under a global licensing,...
Study Being Led by Leading Ocular Oncologist, Carol L. Shields, M.D., Director, Ocular Oncology Service, Wills Eye Hospital CAMBRIDGE, Mass.–(BUSINESS WIRE)– Aura Biosciences, a clinical-stage biopharmaceutical company developing a novel class of tumor targeted therapies for initial application in primary tumors such as choroidal melanoma, today announced the dosing of the first patient in a...
EO2401 is an innovative, off-the-shelf microbiome-antigen (‘OncoMimic’) based immunotherapy candidate EO2401 combines three ‘OncoMimics’ designed to trigger the immune system into recognizing tumor cells as bacterial (i.e. non-self) and eliciting a targeted cell-killing response Clinical trial with EO2401 now underway in two cancer indications: brain cancer (glioblastoma) and adrenal tumors Paris, France and Cambridge, MA,...
Pivotal Phase 3 clinical trial of oral tebipenem HBr met primary endpoint, demonstrating statistical non-inferiority versus intravenous ertapenem in patients with complicated urinary tract infection and acute pyelonephritis Well-tolerated with comparable safety profile to intravenous ertapenem Spero intends to complete NDA submission for U.S. regulatory approval of tebipenem HBr in the second quarter of 2021 Management to host...
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 24 August 2020: Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care...
– MAU868 has the potential to be the first therapeutic to prevent and treat BKVassociated diseases in transplant patients SAN DIEGO – Aug 17, 2020 – Amplyx Pharmaceuticals, a clinical-stage biopharmaceutical company developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, today announced that the first patient has been dosed...
Cambridge, UK and Indianapolis, US – 18 August 2020: Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or chemotherapy, announces that, further to the announcements on...
Cambridge, UK and Indianapolis, US – 14 August 2020: Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or chemotherapy, announces the successful completion of the placing...
Highly selective, potent, small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease BOSTON, Aug. 13, 2020 (GLOBE NEWSWIRE) — Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced...
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014. Acacia Pharma Group plc Interim Results for the Six Months ended 30 June 2020 US approval for BARHEMSYS® for postoperative nausea & vomiting (PONV) US approval of BYFAVO™ for procedural sedation Strategic agreement with Cosmo Technologies providing funding for US...
1 2 3 61

Nyheder

Vægt
Fedme sidder i hjernen
24. september 2020
442 vikingeskeletter fik en tur i DNA-maskinen – nu revideres historien om vikingekulturen
16. september 2020
Håb om at kunne kurere type 2 diabetes med indsprøjtning i hjernen
7. september 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge